Eric Assenat
6PUBLICATIONS
28CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Oct 24, 2025
Reply to: Oxaliplatin Dosing and Toxicity: A Cautionary Perspective on Efficacy.Eric Assenat, Pierre Senesse
|Jun 21, 2025
Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study.Jean-Frédéric Blanc, Mohamed Bouattour, Ludovic Gauthier
|Jun 20, 2025
Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial.Eric Assenat, Meher Ben Abdelghani, Sophie Gourgou
|Apr 04, 2025
Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study).Lilian Schwarz, Jean-Baptiste Bachet, Aurelia Meurisse
|Jan 06, 2021
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1).Eric Assenat, Laurent Mineur, Caroline Mollevi
|May 01, 2019
Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II Trial.Boris Guiu, Patrick Chevallier, Eric Assenat
Pageof 1
Frequent Collaborators
2 joint publications
Pierre Senesse
2 joint publications
Thibault Mazard
1 joint publications
Boris Guiu
1 joint publications
Patrick Chevallier
1 joint publications
Eric Nguyen-Khac
1 joint publications
Jean Gugenheim
1 joint publications
Olivier Chevallier
1 joint publications
Jean-Claude Barbare
1 joint publications
Marc Ychou
1 joint publications
Thomas Walter
